Trending...
- Make Innovation Matter: Support H.R.1's R&D Expensing Relief for American Small Businesses
- Google AI Quietly Corrects the Record on Republic of Aquitaine's Legal Sovereignty
- Chicago: Mayor Brandon Johnson Announces 2026 Budget Engagement Roundtables
CHICAGO ~ MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA" or the "Company"), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, recently announced that it has closed its previously announced registered direct offering for the issuance and sale of an aggregate of 2,424,243 of its shares of common stock at a purchase price of $1.65 per share. In a concurrent private placement, MAIA also issued and sold unregistered warrants to purchase up to an aggregate of 2,424,243 shares of its common stock.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to MAIA from the offering were approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by the Company. MAIA currently intends to use the net proceeds from the offering for working capital and general corporate purposes as well as to fund research and development activities.
More on illi News
The unregistered warrants have an exercise price $1.86 per share, become exercisable six months following issuance and will expire five and one-half years from the date of issuance. The shares of common stock offered in the registered direct offering (but excluding the unregistered warrants offered in the concurrent private placement and the shares of common stock underlying such unregistered warrants) were offered and sold by MAIA pursuant to a "shelf" registration statement on Form S-3 (Registration No. 333-273984), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on August 15, 2023 and declared effective by the SEC on August 23, 2023. The offering was made only by means of a prospectus supplement that forms a part of this registration statement which was filed with SEC and is available on their website located at http://www.sec.gov . Electronic copies may also be obtained by contacting H.C Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor New York NY 10022 or by phone at (212) 856-5711 or e-mail at placements@hcwco.com .
More on illi News
The offer and sale of unregistered warrants in this private placement were made in a transaction not involving a public offering and have not been registered under Section 4(a)(2) of Securities Act 1933 or Rule 506(b) Regulation D promulgated thereunder nor have they been registered under Securities Act or applicable state securities laws; therefore these unregistered warrants offered in this private placement along with underlying shares may not be reoffered or resold in United States except pursuant to an effective registration statement or an applicable exemption from registration requirements under Securities Act or such applicable state securities laws .
MAIA Biotechnology Inc., is focused on developing first-in-class drugs with novel mechanisms that are intended to improve lives people with cancer; their lead program is THIO which is being developed for treatment NSCLC patients with telomerase positive cancer cells . For more information please visit www .maiabiotech .com
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to MAIA from the offering were approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by the Company. MAIA currently intends to use the net proceeds from the offering for working capital and general corporate purposes as well as to fund research and development activities.
More on illi News
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
- The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
- Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
The unregistered warrants have an exercise price $1.86 per share, become exercisable six months following issuance and will expire five and one-half years from the date of issuance. The shares of common stock offered in the registered direct offering (but excluding the unregistered warrants offered in the concurrent private placement and the shares of common stock underlying such unregistered warrants) were offered and sold by MAIA pursuant to a "shelf" registration statement on Form S-3 (Registration No. 333-273984), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on August 15, 2023 and declared effective by the SEC on August 23, 2023. The offering was made only by means of a prospectus supplement that forms a part of this registration statement which was filed with SEC and is available on their website located at http://www.sec.gov . Electronic copies may also be obtained by contacting H.C Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor New York NY 10022 or by phone at (212) 856-5711 or e-mail at placements@hcwco.com .
More on illi News
- The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
- Digital Watchdog Launches New myDW Cloud Services
- Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
- Drone Light Shows Emerge as the New Standard in Live Event Entertainment
- Lore Link is Here to Help Organize Your Game
The offer and sale of unregistered warrants in this private placement were made in a transaction not involving a public offering and have not been registered under Section 4(a)(2) of Securities Act 1933 or Rule 506(b) Regulation D promulgated thereunder nor have they been registered under Securities Act or applicable state securities laws; therefore these unregistered warrants offered in this private placement along with underlying shares may not be reoffered or resold in United States except pursuant to an effective registration statement or an applicable exemption from registration requirements under Securities Act or such applicable state securities laws .
MAIA Biotechnology Inc., is focused on developing first-in-class drugs with novel mechanisms that are intended to improve lives people with cancer; their lead program is THIO which is being developed for treatment NSCLC patients with telomerase positive cancer cells . For more information please visit www .maiabiotech .com
Filed Under: Business
0 Comments
Latest on illi News
- ALIVE and KICKING: LAUGHTER NEVER GETS OLD has its World Premiere July 11-20 in St. Charles, IL
- AAR to announce fourth quarter fiscal year 2025 results on July 16, 2025
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- New Dad Battles Leukemia and Wins!
- Kefir Comes to NASCAR as Lifeway Foods Races into Hometown Weekend with Driver Josh Bilicki at The Loop 110
- Recession-Proof Startups: What Business Plans Investors Are Actually Funding in 2025
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
- $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
- City of Chicago Releases Annual Comprehensive Financial Report for Fiscal Year 2024
- Indies United is pleased to present our July 2025 book releases
- Endurance Warranty Earns 2025 Buyer's Choice Awards from ConsumerAffairs Through Verified Customer Reviews
- Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
- Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
- Naperville: Structure Fire in the 1600 Block of Country Lakes Drive
- Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
- Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
- Bak Brothers, Inc. Expands Exterior Remodeling Services to La Grange, IL
- AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
- The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence